{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:15:59Z","timestamp":1791404159661,"version":"4.3.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Caisse Nationale d'Assurance Maladie"},{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40259-023-00584-8","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T10:12:35Z","timestamp":1678097555000},"page":"397-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-7517","authenticated-orcid":false,"given":"Hugo","family":"Jourdain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-5142","authenticated-orcid":false,"given":"L\u00e9a","family":"Hoisnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-5270","authenticated-orcid":false,"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-4217","authenticated-orcid":false,"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"issue":"10","key":"584_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232\u201373. https:\/\/doi.org\/10.1007\/s12325-017-0612-x.","journal-title":"Adv Ther"},{"issue":"11","key":"584_CR2","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s10067-019-04699-8","volume":"38","author":"S Tavakolpour","year":"2019","unstructured":"Tavakolpour S, et al. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol. 2019;38(11):2977\u201394. https:\/\/doi.org\/10.1007\/s10067-019-04699-8.","journal-title":"Clin Rheumatol"},{"key":"584_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-017-0632-1","author":"RI Hassan","year":"2017","unstructured":"Hassan RI, Gaffo AL. Rituximab in ANCA-associated vasculitis. Curr Rheumatol Rep. 2017. https:\/\/doi.org\/10.1007\/s11926-017-0632-1.","journal-title":"Curr Rheumatol Rep."},{"issue":"1","key":"584_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40257-019-00497-9","volume":"21","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol. 2020;21(1):149\u201356. https:\/\/doi.org\/10.1007\/s40257-019-00497-9.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"584_CR5","doi-asserted-by":"publisher","first-page":"107.e1","DOI":"10.1016\/j.jaip.2016.06.022","volume":"5","author":"AS Levin","year":"2017","unstructured":"Levin AS, Otani IM, Lax T, Hochberg E, Banerji A. Reactions to rituximab in an outpatient infusion center: a 5-year review. J Allergy Clin Immunol Pract. 2017;5(1):107.e1-113.e1. https:\/\/doi.org\/10.1016\/j.jaip.2016.06.022.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"4","key":"584_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","volume":"15","author":"F Paul","year":"2019","unstructured":"Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15(4):383\u20139. https:\/\/doi.org\/10.1080\/1744666X.2019.1562905.","journal-title":"Expert Rev Clin Immunol"},{"key":"584_CR7","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"584_CR8","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","volume":"4","author":"WS Kim","year":"2017","unstructured":"Kim WS, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017;4(8):e362\u201373. https:\/\/doi.org\/10.1016\/S2352-3026(17)30120-5.","journal-title":"Lancet Haematol."},{"issue":"8","key":"584_CR9","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","volume":"4","author":"W Jurczak","year":"2017","unstructured":"Jurczak W, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350\u201361. https:\/\/doi.org\/10.1016\/S2352-3026(17)30106-0.","journal-title":"Lancet Haematol."},{"issue":"2","key":"584_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40259-019-00398-7","volume":"34","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, et al. A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera\u00ae) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL). BioDrugs. 2020;34(2):171\u201381. https:\/\/doi.org\/10.1007\/s40259-019-00398-7.","journal-title":"BioDrugs"},{"key":"584_CR11","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/j.jval.2018.09.1007","volume":"21","author":"A Franceschetti","year":"2018","unstructured":"Franceschetti A, Baskett A, Baynton E, Baldock D, Karki C. Comparative analysis of biosimilar rituximab usage in treating non-Hodgkin lymphoma and rheumatoid arthritis: results from a multi-country study in Europe. Value Health. 2018;21:S169. https:\/\/doi.org\/10.1016\/j.jval.2018.09.1007.","journal-title":"Value Health."},{"issue":"15","key":"584_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2217\/fon-2020-0180","volume":"16","author":"B Otremba","year":"2020","unstructured":"Otremba B, Borchardt J, Kuske A, Hollnagel-Schmitz M, Losch FO. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany. Future Oncol. 2020;16(15):1001\u201312. https:\/\/doi.org\/10.2217\/fon-2020-0180.","journal-title":"Future Oncol"},{"issue":"2","key":"584_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12288-017-0885-x","volume":"34","author":"G Prakash","year":"2018","unstructured":"Prakash G, et al. Infusion related hypersensitivity reactions with bio-similar anti cd-20 monoclonal antibody rituximab in Indian patients: a retrospective study. Indian J Hematol Blood Transfus. 2018;34(2):273\u20137. https:\/\/doi.org\/10.1007\/s12288-017-0885-x.","journal-title":"Indian J Hematol Blood Transfus."},{"issue":"11","key":"584_CR14","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/rheumatology\/kex268","volume":"56","author":"M Scherlinger","year":"2017","unstructured":"Scherlinger M, Schaeverbeke T, Truchetet M-E. Serum sickness-like disease after switching to biosimilar infliximab. Rheumatology (Oxford). 2017;56(11):2032\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/kex268.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"584_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","volume":"45","author":"P Karmacharya","year":"2015","unstructured":"Karmacharya P, et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum. 2015;45(3):334\u201340. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.014.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"584_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/acr.23771","volume":"71","author":"H Tony","year":"2019","unstructured":"Tony H, et al. Safety and immunogenicity of rituximab biosimilar GP2013 after switch from reference rituximab in patients with active rheumatoid arthritis. Arthritis Care Res. 2019;71(1):88\u201394. https:\/\/doi.org\/10.1002\/acr.23771.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"584_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","volume":"34","author":"V Strand","year":"2020","unstructured":"Strand V, Gon\u00e7alves J, Hickling TP, Jones HE, Marshall L, Isaacs JD. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs. 2020;34(1):27\u201337. https:\/\/doi.org\/10.1007\/s40259-019-00394-x.","journal-title":"BioDrugs"},{"issue":"1","key":"584_CR18","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1038\/s41598-021-85563-1","volume":"11","author":"SAM Urru","year":"2021","unstructured":"Urru SAM, SpilaAlegiani S, Guella A, Traversa G, Campomori A. Safety of switching between rituximab biosimilars in onco-hematology. Sci Rep. 2021;11(1):5956. https:\/\/doi.org\/10.1038\/s41598-021-85563-1.","journal-title":"Sci Rep"},{"issue":"26","key":"584_CR19","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2217\/fon-2020-0131","volume":"16","author":"P Nava-Parada","year":"2020","unstructured":"Nava-Parada P, Shelbaya A, Nabhan C. Rituximab biosimilars in hematologic malignancies: the need for a real-world approach. Future Oncol. 2020;16(26):2017\u201327. https:\/\/doi.org\/10.2217\/fon-2020-0131.","journal-title":"Future Oncol"},{"key":"584_CR20","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, et al. Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique. 2017;65:S149\u201367. https:\/\/doi.org\/10.1016\/j.respe.2017.05.004.","journal-title":"Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique."},{"issue":"2","key":"584_CR21","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1111\/aos.14929","volume":"100","author":"S Billioti","year":"2022","unstructured":"Billioti S, de Gage M, Bertrand SG, Zureik M. Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal nationwide observational study. Acta Ophthalmol. 2022;100(2):e502\u201311. https:\/\/doi.org\/10.1111\/aos.14929.","journal-title":"Acta Ophthalmol"},{"key":"584_CR22","doi-asserted-by":"publisher","first-page":"n37","DOI":"10.1136\/bmj.n37","volume":"372","author":"A Weill","year":"2021","unstructured":"Weill A, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. 2021;372:n37. https:\/\/doi.org\/10.1136\/bmj.n37.","journal-title":"BMJ"},{"key":"584_CR23","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.lanepe.2021.100158","volume":"8","author":"L Semenzato","year":"2021","unstructured":"Semenzato L, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Regional Health Europe. 2021;8:100158. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100158.","journal-title":"Lancet Regional Health Europe."},{"issue":"3","key":"584_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0961203320982668","volume":"30","author":"M Leandro","year":"2021","unstructured":"Leandro M, Isenberg DA. Rituximab\u2014the first twenty years. Lupus. 2021;30(3):371\u20137. https:\/\/doi.org\/10.1177\/0961203320982668.","journal-title":"Lupus"},{"issue":"1","key":"584_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","volume":"269","author":"CG Chisari","year":"2022","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022;269(1):159\u201383. https:\/\/doi.org\/10.1007\/s00415-020-10362-z.","journal-title":"J Neurol"},{"issue":"2","key":"584_CR26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ame2.12064","volume":"2","author":"K Chauhan","year":"2019","unstructured":"Chauhan K, Mehta AA. Rituximab in kidney disease and transplant. Anim Models Exp Med. 2019;2(2):76\u201382.","journal-title":"Anim Models Exp Med."},{"issue":"10","key":"584_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/pds.4877","volume":"28","author":"YM Mesfin","year":"2019","unstructured":"Mesfin YM, Cheng AC, Tran AHL, Buttery J. Positive predictive value of ICD-10 codes to detect anaphylaxis due to vaccination: a validation study. Pharmacoepidemiol Drug Saf. 2019;28(10):1353\u201360. https:\/\/doi.org\/10.1002\/pds.4877.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"584_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.anai.2019.11.026","volume":"124","author":"KL Tuttle","year":"2020","unstructured":"Tuttle KL, Wickner P. Capturing anaphylaxis through medical records. Ann Allergy Asthma Immunol. 2020;124(2):150\u20135. https:\/\/doi.org\/10.1016\/j.anai.2019.11.026.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"584_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/alr.22293","volume":"9","author":"MR Chaaban","year":"2019","unstructured":"Chaaban MR, Warren Z, Baillargeon JG, Baillargeon G, Resto V, Kuo Y. Epidemiology and trends of anaphylaxis in the United States, 2004\u20132016. Int Forum Allergy Rhinol. 2019;9(6):607\u201314. https:\/\/doi.org\/10.1002\/alr.22293.","journal-title":"Int Forum Allergy Rhinol."},{"issue":"38","key":"584_CR30","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1016\/j.vaccine.2021.08.004","volume":"39","author":"R Goud","year":"2021","unstructured":"Goud R, et al. ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis incidence in Medicare. Vaccine. 2021;39(38):5368\u201375. https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.004.","journal-title":"Vaccine"},{"key":"584_CR31","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria; 2022. https:\/\/www.R-project.org. Accessed 24 Nov 2022."},{"key":"584_CR32","unstructured":"Wickham H, Fran\u00e7ois R, Henry L, M\u00fcller K. dplyr: A grammar of data manipulation. 2022. https:\/\/dplyr.tidyverse.org\/. Accessed 24 Nov 2022."},{"key":"584_CR33","doi-asserted-by":"crossref","unstructured":"Wickham H. ggplot2: Elegant graphics for data analysis. New York: Springer; 2016. https:\/\/ggplot2.tidyverse.org.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"584_CR34","unstructured":"Therneau TM. A package for survival analysis in R. Mayo Clinic; 2022. https:\/\/CRAN.R-project.org\/package=survival."},{"issue":"4","key":"584_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40259-021-00487-6","volume":"35","author":"J Courville","year":"2021","unstructured":"Courville J, et al. Factors influencing infusion-related reactions following dosing of reference rituximab and PF-05280586, a rituximab biosimilar. BioDrugs. 2021;35(4):459\u201368. https:\/\/doi.org\/10.1007\/s40259-021-00487-6.","journal-title":"BioDrugs"},{"issue":"1","key":"584_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-017-0256-z","volume":"32","author":"RA McKinnon","year":"2018","unstructured":"McKinnon RA, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs. 2018;32(1):27\u201352. https:\/\/doi.org\/10.1007\/s40259-017-0256-z.","journal-title":"BioDrugs"},{"issue":"4","key":"584_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463\u201378. https:\/\/doi.org\/10.1007\/s40265-018-0881-y.","journal-title":"Drugs"},{"issue":"2","key":"584_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40259-017-0210-0","volume":"31","author":"P Kurki","year":"2017","unstructured":"Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83\u201391. https:\/\/doi.org\/10.1007\/s40259-017-0210-0.","journal-title":"BioDrugs"},{"issue":"4","key":"584_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5114\/reum.2018.77975","volume":"56","author":"P Wiland","year":"2018","unstructured":"Wiland P, et al. Biosimilar switching\u2014current state of knowledge. Reumatologia. 2018;56(4):234\u201342. https:\/\/doi.org\/10.5114\/reum.2018.77975.","journal-title":"Reumatologia"},{"issue":"4","key":"584_CR40","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734\u201355. https:\/\/doi.org\/10.1002\/cpt.1836.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"584_CR41","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-021-01601-2","volume":"81","author":"P Kurki","year":"2021","unstructured":"Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81(16):1881\u201396. https:\/\/doi.org\/10.1007\/s40265-021-01601-2.","journal-title":"Drugs"},{"issue":"10","key":"584_CR42","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.drudis.2019.06.016","volume":"24","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24(10):1963\u20137. https:\/\/doi.org\/10.1016\/j.drudis.2019.06.016.","journal-title":"Drug Discov Today"},{"issue":"7","key":"584_CR43","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1080\/10428194.2020.1742906","volume":"61","author":"K Lee","year":"2020","unstructured":"Lee K, et al. The clinical outcomes of rituximab biosimilar CT-P10 (Truxima\u00ae) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. Leuk Lymphoma. 2020;61(7):1575\u201383. https:\/\/doi.org\/10.1080\/10428194.2020.1742906.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"584_CR44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/pai.13114","volume":"30","author":"O Soyer","year":"2019","unstructured":"Soyer O, et al. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases. Pediatr Allergy Immunol. 2019;30(8):833\u201340. https:\/\/doi.org\/10.1111\/pai.13114.","journal-title":"Pediatr Allergy Immunol"},{"key":"584_CR45","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fimmu.2017.00614","volume":"8","author":"MI Monta\u00f1ez","year":"2017","unstructured":"Monta\u00f1ez MI, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front Immunol. 2017;8:614. https:\/\/doi.org\/10.3389\/fimmu.2017.00614.","journal-title":"Front Immunol"},{"key":"584_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","volume":"67","author":"G Bayer","year":"2019","unstructured":"Bayer G, et al. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study. Eur J Intern Med. 2019;67:59\u201364. https:\/\/doi.org\/10.1016\/j.ejim.2019.06.009.","journal-title":"Eur J Intern Med"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00584-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00584-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00584-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T09:56:07Z","timestamp":1702029367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00584-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00584-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"7 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are employees of the French National Health Insurance (CNAM), the French National Agency for Medicines and Health Products Safety (ANSM) and the Assistance Publique-H\u00f4pitaux de Paris (AP-HP) and received no funding for this study. The funding source did not intervene at any step of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hugo Jourdain, L\u00e9a Hoisnard, Emilie Sbidian, and Mahmoud Zureik have no conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"EPI-PHARE has permanent regulatory access to the data via its constitutive bodies ANSM and CNAM, thus this present work did not require approval from the French Data Protection Authority (CNIL). The study was registered on the EPI-PHARE study register.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Given that the data are anonymous, no informed consent to participate or publish was required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"In accordance with data protection legislation and the French regulation, the authors cannot publicly release the data from the French National Health Data System.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Literature search: All authors. Study design: All authors. Data extraction and collection: HJ. Statistical analysis: HJ. Interpretation of the results. All authors. Drafting of the manuscript: HJ. Revision of the manuscript. All authors. Supervision: ES, MZ. All authors confirm that they had full access to all the data in the study and accept responsibility to submit the manuscript for publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}